Eculizumab treatment alters the proteometabolome beyond the inhibition of complement
Therapeutic strategies targeting complement have revolutionized the treatment of myasthenia gravis (MG). However, a deeper understanding of complement modulation in the human system is required to improve treatment responses and identify off-target effects shaping long-term outcomes. For this reason...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , , , , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
American Society for Clinical investigation
2023-07-01
|
| Seri Bilgileri: | JCI Insight |
| Konular: | |
| Online Erişim: | https://doi.org/10.1172/jci.insight.169135 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|